Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.

Journal of clinical pathology - 1 Jan 2017

Richman Susan D, Fairley Jennifer, Butler Rachel, Deans Zandra C

Abstract excerpt

AIMS: Since 2008, KRAS mutation status in exon 2 has been used to predict response to anti-EGFR therapies. Recent evidence has demonstrated that NRAS status is also predictive of response. Several retrospective 'extended RAS' analyses have been performed on clinical trial material. Despite this, are we really moving towards such extended screening practice in reality? METHODS: Data were analysed from four...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mutational Analysis
Share to NRAS gene
Share to Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Time Factors

Share to United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 27681846
DOI: 10.1136/jclinpath-2016-203822
PMCID: PMC5256378

Genes

KRAS
NRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.PMID 27681846Read ↗

External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

Results of the UK NEQAS for Molecular Genetics reference sample analysis.Semantic proximity Read ↗

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.Semantic proximity Read ↗

RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.Semantic proximity Read ↗

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.Semantic proximity Read ↗

The UK NEQAS for Molecular Genetics scheme for gastrointestinal stromal tumour: findings and recommendations following four rounds of circulation.Semantic proximity Read ↗

Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.Semantic proximity Read ↗

The RAS testing in real world management of metastatic colorectal cancer: The results of Italian Laboratories Survey.Semantic proximity Read ↗

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.Semantic proximity Read ↗

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.Semantic proximity Read ↗

Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.Semantic proximity Read ↗

Germline mismatch repair (MMR) gene analyses from English NHS regional molecular genomics laboratories 1996–2020: development of a national resource of patient-level genomics laboratory recordsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.